BioAge Labs to Participate in Truist Symposium on AI-driven Drug Discovery, Multiple Upcoming Biotech Investment Conferences
CEO and CFO available for investor meetings at Truist Securities Life Sciences AI Symposium (March 1), SVB Leerink Biopharma Private Company Connect (March 29–31), and Needham Virtual Healthcare Conference (April 11–14)
RICHMOND, Calif.–(BUSINESS WIRE)–#aging–BioAge Labs, Inc. (link), a clinical-stage biotechnology company and global leader in using artificial intelligence (AI) and machine learning (ML) to develop drugs that target the molecular causes of aging, today announced that the Company will participate in a panel discussion at the Truist Securities Life Sciences AI Symposium, the first of three investment banking corporate access events to which BioAge will contribute in the coming two months.
BioAge CEO and co-founder Kristen Fortney, PhD, will speak on the panel “Integrated platforms for AI-based drug discovery” on March 1, 2022 from 11:20 AM to 12:20 PM EST. Additional panelists include Carl Hansen, CEO of AbCellera Biologics; Don Bergstrom, President of R&D at Relay Therapeutics; Abraham Heifets, CEO and Jonathan Barr, CFO of Atomwise; and Krishnan Nandabalan, CEO of InveniAI. Robyn Karnauskas, Senior Research Analyst and Kripa Devarakonda, Research Analyst, Truist Securities will moderate. The event will be held virtually.
A live audio webcast may be accessed through the conference website: https://truist-securities-2022-ai-symposium-biotech-tools.videoshowcase.net/login. (In the login form, enter ‘BioAge Labs’ in the ‘Sales Contact’ field.)
BioAge uses its discovery platform, which combines AI and ML analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging, thus revealing the causes of age-related disease. By targeting the mechanisms of aging with a mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat or even prevent these diseases in entirely new ways. BioAge currently has three clinical-stage programs in its growing portfolio.
From March 29 to March 31, 2022, BioAge will participate in SVB Leerink Biopharma Private Company Connect, an event intended to bring together private companies with institutional investors and to facilitate discussions on the trends and opportunities shaping the future of healthcare.
From April 11 to April 14, 2022, BioAge will participate in the 21st Annual Needham Virtual Healthcare Conference, which features presentations from leading public and private companies in the biotechnology, specialty pharmaceuticals, medical technology, and diagnostics sectors.
At all three events, both CEO Kristen Fortney, PhD, and CFO Dov Goldstein, MD, MBA will be available to meet with qualified institutional, private equity, and venture capital investors. Investors seeking to participate in these events should contact media@bioagelabs.com.
Contacts
BioAge | Chris Patil | media@bioagelabs.com
